만성 조현병 입원환자에서의 QTc 간격 연장과 관련된 요인

키워드

참고문헌 (40)

1. Koponen H, "Schizophrenia and sudden cardiac death", Nordic J Psychiatry, 62, pp.342~345 (2008)[DOI]
2. Faber TS, "Drug-induced torsade de pointes", Drug Safety, 11, pp.463~466 (1994)[DOI]
3. Algra A, "QTc prolongation measured by standard 12-lead electrocardiography is an independent risk factor for sudden death due to cardiac arrest", Circulation, 83(6), pp.1888~1894 (1991)[DOI]
4. Fayssoil A, "Torsade de pointes induced by citalopram and amiodarone", Annales de Cardiologie et D'angeiologie, 60, pp.165~168 (2011)[DOI]
5. Moss AJ, "Measurement of the QT interval and the risk associated with QTc interval prolongation: a review", Am J Cardiol, 72, pp.23~25 (1993)[DOI]
6. Glassman AH, "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death", Am J Psychiatry, 158, pp.1774~1782 (2001)[DOI]
7. Shader RI, "Potassium, antipsychotic agents, arrhythmias, and sudden death", J Clin Psychopharmacology, 18, pp.427~428 (1998)[DOI]
8. Beach SR, "QTc prolongation, torsades de pointes, and psychotropic medications", Psychosomatics, 54, pp.1~13 (2013)[DOI]
9. Roden DM, "Drug-induced prolongation of the QT interval", N Engl J Med, 350, pp.1013~1022 (2004)[DOI]
10. Zemrak WR, "Association of antipsychotic and antidepressant drugs with QT interval prolongation", Am J Health-System Pharm, 65, pp.1029~1038 (2008)[DOI]
11. Chong SA, "Prolonged QTc intervals in medicated patients with schizophrenia", Hum Psychopharmacol, 18, pp.647~649 (2003)[DOI]
12. Information for healthcare professionals: haloperidol, "US Food and Drug Administration", Center for drug evaluation and research, ~ (2007)
13. Harrigan EP, "A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition", J Clin Psychopharmacol, 24, pp.62~69 (2004)[DOI]
14. Isbister GK, "Amisulpride deliberate self-poisoning causing severe cardiac toxicity including QT prolongation and torsades de pointes", Med J Aust, 184, pp.354~ (2006)
15. Gallego JA, "Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009", Schizophr Res, 138, pp.18~28 (2012)[DOI]
16. Michelsen JW, "Cardiovascular effects of antipsychotics", Expert Rev Neurother, 7, pp.829~839 (2007)[DOI]
17. Barbui C, "Antipsychotic dose mediates the association between polypharmacy and corrected QT interval", PloS one, 11, pp.e0148212~ (2016)[DOI]
18. Takeuchi H, "Antipsychotic polypharmacy and corrected QT interval: a systematic review", Can J Psychiatry, 60, pp.215~222 (2015)[DOI]
19. Ramos-Rios R, "QTc interval in a sample of long-term schizophrenia inpatients", Schizophr Res, 116, pp.35~43 (2010)[DOI]
20. Reilly JG, "QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients", Lancet, 355, pp.1048~1052 (2000)[DOI]
21. American Psychiatric Association, "Diagnostic and statistical manual of mental disorders(DSM-5(R))" (2013), American psychiatric pub
22. 양병화, "다변량 데이터 분석법의 이해", pp.64~ (2006), 커뮤니케이션북스
23. Woods SW, "Chlorpromazine equivalent doses for the newer atypical antipsychotics", J Clin Psychiatry, 64, pp.663~667 (2003)[DOI]
24. Sweileh WM, "Evaluation of defined daily dose, percentage of british national formulary maximum and chlorpromazine equivalents in antipsychotic drug utilization", Saudi Pharm J, 22, pp.127~132 (2014)[DOI]
25. Rey MJ, "Guideline for the dosage of neuroleptics. I: chlorpromazine equivalents of orally administered neuroleptics", Int Clin Psychopharmacol, 4, pp.95~104 (1989)[DOI]
26. Aiken LS, "Multiple regression: Testing and interpreting interactions" (1991), Sage
27. Ozeki Y, "Risk factors of QT interval prolongation in japanese patients with schizophrenia", Inter J Neuropsychopharm, 11, pp.149~ (2008)
28. Katharina W, "QTc prolongation by psychotropic drugs and the risk of torsade de pointes", Dtsch Arztebl Int, 108(41), pp.687~ (2011)
29. Haddad PM, "Antipsychotic-related QTc prolongation, torsade de pointes and sudden death", Drugs, 62, pp.1649~1671 (2002)[DOI]
30. 박민경, "조현병 환자에서 QT 간격 지연과 흡연의 연관성", 생물치료정신의학, 18(2), pp.238~245 (2012), 대한생물치료정신의학회
31. Bahaoddini A, "Genetic polymorphism of glutathione S-transferase T1(GSTT1) and QT-interval in schizophrenia patients", J Mol Neurosci, 38, pp.173~ (2009)[DOI]
32. Okayasu H, "Pharmacotherapeutic determinants for QTc interval prolongation in Japanese patients with mood disorder", Pharmacopsychiatry, 45, pp.79~83 (2012)[DOI]
33. Lohr JB, "Smoking and schizophrenia", Schizophr Res, 8, pp.93~102 (1992)[DOI]
34. Desai HD, "Smoking in patients receiving psychotropic medications", CNS Drugs, 15, pp.469~494 (2001)[DOI]
35. Arslan E, "Effect of uncomplicated obesity on QT interval in young men", Pol Arch Med Wewn, 120, pp.209~213 (2010)
36. Huikuri HV, "Sudden death due to cardiac arrhythmias", N Engl J Med, 346, pp.946~947 (2002)[DOI]
37. Faramawi MF, "The association of the metabolic syndrome with QTc interval in NHANES III", Eur J Epidemiol, 23, pp.459~ (2008)[DOI]
38. Wirshing DA, "Schizophrenia and obesity: impact of antipsychotic medications", J Clin Psychiatry, 65, pp.13~26 (2003)
39. Wenzel-Seifert K, "QTc prolongation by psychotropic drugs and the risk of torsade de pointes", Dtsch Arztebl Int, 108, pp.687~693 (2011)
40. Wolf ME, "Lithium therapy, hypercalcemia, and hyperparathyroidism", Am J Ther, 4, pp.323~326 (1997)[DOI]

관련 논문AI추천